Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GT Biopharma ( (GTBP) ) has provided an update.
On April 3, 2026, GT Biopharma, Inc. entered into an Investigator Initiated Clinical Trial Agreement with the Regents of the University of Minnesota, under which the university will sponsor an IND application and act as sponsor investigator for a phase 1a/1b trial of GTB-5550 in select advanced solid tumors that have failed prior treatment. The three-year research program, budgeted at up to approximately $3.8 million funded by GT Biopharma, allows both parties to publish the study results and includes provisions for termination by either side under specified notice and breach conditions.
The agreement supports clinical research use of GTB-5550 and positions GT Biopharma to advance its B7-H3-targeting TriKE candidate into early-stage human testing in a challenging patient population. This collaboration with a major academic institution may help validate the company’s technology platform while distributing operational responsibilities and providing structured exit options if safety, welfare, or contractual issues arise.
The most recent analyst rating on (GTBP) stock is a Hold with a $0.39 price target. To see the full list of analyst forecasts on GT Biopharma stock, see the GTBP Stock Forecast page.
Spark’s Take on GTBP Stock
According to Spark, TipRanks’ AI Analyst, GTBP is a Neutral.
The score is primarily weighed down by weak financial performance—no revenue, large ongoing losses, and persistent cash burn that imply continued financing needs. Technicals add pressure as the stock trades below major moving averages with negative MACD. Valuation contributes limited support because a negative P/E reflects unprofitability and no dividend yield is provided.
To see Spark’s full report on GTBP stock, click here.
More about GT Biopharma
GT Biopharma, Inc. is a biotechnology company developing immuno-oncology therapeutics, with a focus on Tri-Specific Killer Engager (TriKE) platforms targeting difficult-to-treat cancers. Its pipeline includes GTB-5550, a camelid nanobody-based B7-H3 TriKE designed for use in advanced solid tumors that have failed prior therapy.
Average Trading Volume: 1,133,164
Technical Sentiment Signal: Sell
Current Market Cap: $14.04M
See more insights into GTBP stock on TipRanks’ Stock Analysis page.